A clear explanation of immunotherapy, how it helps the immune system recognize and fight cancer, which cancers it can treat, and why it works better for some patients than others.
FOLFOX: What It Is, How It Works and What to Expect
CANCERSNOOP TREATMENT GUIDE
FOLFOX chemotherapy is one of the most established treatment regimens used for colorectal cancer.
It combines three medicines and can be used in different situations—from reducing the risk of cancer returning after surgery to treating advanced or metastatic colorectal cancer.
The short answer
FOLFOX is a chemotherapy regimen used extensively in colorectal cancer.
It combines three medicines: folinic acid (leucovorin), fluorouracil (5-FU) and oxaliplatin.
Depending on the situation, FOLFOX may be given after surgery to reduce the risk of recurrence or used to shrink and control advanced or metastatic colorectal cancer.
It is an established treatment supported by clinical trials and international treatment guidelines—but like all chemotherapy, its potential benefits have to be balanced against its side effects.
FOL
Folinic acid
Also called leucovorin. It enhances the effect of fluorouracil.
F
Fluorouracil
Usually called 5-FU. It interferes with processes cancer cells need to grow and divide.
OX
Oxaliplatin
A platinum chemotherapy drug that damages DNA and interferes with cancer-cell division.
What exactly is FOLFOX chemotherapy?
FOLFOX is not one drug. It is the name of a chemotherapy combination.
The name comes from the medicines used in the regimen:
FOL — folinic acid (leucovorin)
F — fluorouracil (5-FU)
OX — oxaliplatin
Using medicines that attack cancer cells through different mechanisms can make the combination more effective than relying on one drug alone in situations where FOLFOX is appropriate.
When is FOLFOX used?
FOLFOX can be used at different points in colorectal cancer treatment. The reason for giving it depends heavily on the stage of the cancer and the overall treatment strategy.
After surgery
FOLFOX can be used as adjuvant chemotherapy after surgery, particularly in stage III colon cancer, to reduce the risk that microscopic cancer cells left elsewhere in the body will later cause recurrence.
Advanced or metastatic disease
FOLFOX is also an established systemic treatment option for metastatic colorectal cancer. Depending on tumor biology and the treatment plan, other medicines may be added to chemotherapy.
As part of a strategy toward local treatment
In selected patients with metastatic disease, systemic treatment may shrink or control metastases enough for surgery, ablation or another local treatment to become possible. Whether this strategy is realistic depends on the individual case and should be assessed by a multidisciplinary cancer team.
How does FOLFOX work?
The three medicines have different roles.
Fluorouracil (5-FU) interferes with processes involved in DNA and RNA production that rapidly dividing cells need.
Folinic acid is not being used here as another cancer-killing chemotherapy drug. It helps strengthen and prolong the effect of 5-FU on its target.
Oxaliplatin forms abnormal links within DNA, interfering with the ability of cells to copy and repair their genetic material.
In plain language
FOLFOX attacks processes cancer cells need to divide and survive. But chemotherapy can also affect healthy rapidly dividing cells, which is why side effects occur.
What does a FOLFOX cycle look like?
FOLFOX is given intravenously in treatment cycles. There are several versions of the regimen, so the exact doses and timing can differ.
A commonly used schedule is repeated approximately every two weeks.
1
Infusion treatment
Oxaliplatin and folinic acid are given intravenously. Fluorouracil is then administered according to the specific FOLFOX protocol being used.
2
Continuous 5-FU
In commonly used FOLFOX regimens, part of the 5-FU treatment is delivered continuously over approximately 46 hours, often through a portable infusion pump.
3
Recovery period
The remaining days allow the body time to recover before the next cycle. Blood tests and symptoms are monitored throughout treatment.
What side effects can FOLFOX cause?
Not everyone experiences the same side effects or the same severity. Side effects can also change as treatment continues.
Possible side effects include:
• fatigue
• nausea or vomiting
• diarrhea
• mouth soreness
• appetite changes
• reduced blood-cell counts
• increased infection risk
• tingling or numbness in the hands and feet
• sensitivity to cold
The oncology team monitors symptoms and blood results because treatment sometimes needs to be delayed, reduced or adjusted.
OXALIPLATIN & COLD
Cold sensitivity is a characteristic effect of oxaliplatin.
Some people experience tingling, discomfort or unusual sensations when touching cold objects, drinking cold liquids or breathing cold air after oxaliplatin. These symptoms may be temporary, particularly early in treatment, but neuropathy can become more persistent as cumulative exposure increases.
Why does neuropathy matter so much with FOLFOX?
Peripheral neuropathy is one of the most important toxicities associated with oxaliplatin.
It can cause tingling, numbness or altered sensation, usually beginning in the fingers and toes. Some symptoms occur shortly after treatment and improve, while cumulative neuropathy can become longer lasting.
This matters because doctors may reduce the oxaliplatin dose, delay treatment or stop oxaliplatin while continuing other parts of therapy when neuropathy becomes significant.
IMPORTANT
Tell your oncology team about neuropathy early.
Do not wait until numbness or tingling becomes severe. Changes in symptoms can help the treatment team decide whether oxaliplatin exposure should be adjusted.
How long is FOLFOX given?
There is no single treatment duration that applies to everyone.
Duration depends on why FOLFOX is being given, the stage of the cancer, the regimen being used, response to treatment, side effects and the overall treatment strategy.
For adjuvant treatment after surgery, large randomized studies have examined whether shorter courses of oxaliplatin-based chemotherapy can provide similar cancer control while reducing toxicity compared with longer treatment.
The answer depends partly on the chemotherapy regimen and the patient’s recurrence risk. This is why treatment duration should be an individualized oncology decision rather than a fixed number copied from another patient’s treatment plan.
Does reducing a dose mean the treatment has failed?
No.
Chemotherapy doses and schedules are sometimes adjusted because of neuropathy, blood counts, gastrointestinal side effects or other toxicities.
A dose reduction, delay or change does not automatically mean treatment is ineffective. It can be part of safely managing therapy so that the balance between benefit and toxicity remains appropriate.
The significance of any dose change depends on the individual treatment goal and should be discussed with the oncology team.
Can other cancer medicines be added to FOLFOX?
Yes, particularly in metastatic colorectal cancer.
Depending on the tumor’s molecular characteristics, location, previous treatment and other clinical factors, FOLFOX may be combined with targeted or biologic therapies.
This is one reason molecular testing matters in advanced colorectal cancer. Biomarkers such as KRAS, NRAS, BRAF and mismatch repair/microsatellite instability (MMR/MSI) can influence the broader treatment strategy.
Key distinction
These biomarkers do not simply determine whether FOLFOX “works.” They help doctors understand the tumor and choose the broader treatment strategy, including whether other therapies may be appropriate.
What does the evidence say about FOLFOX?
Oxaliplatin combined with fluoropyrimidine-based chemotherapy is an established part of colorectal cancer treatment and is supported by randomized clinical trials, pooled analyses and international clinical guidelines.
For stage III colon cancer, oxaliplatin-based adjuvant chemotherapy has become an established treatment approach after surgery for appropriate patients.
More recent research has also examined how long oxaliplatin-based adjuvant treatment needs to continue. A 2024 meta-analysis of randomized trials involving more than 10,000 patients evaluated shorter versus longer durations of adjuvant chemotherapy, reflecting the ongoing effort to preserve treatment benefit while reducing cumulative toxicity such as neuropathy.
For metastatic colorectal cancer, current ESMO clinical guidance continues to include oxaliplatin-based chemotherapy among established systemic treatment strategies, with treatment selection increasingly shaped by molecular characteristics and the overall therapeutic goal.
CANCERSNOOP BOTTOM LINE
FOLFOX is established treatment. The important question is how it fits your situation.
FOLFOX has a well-established role in colorectal cancer, both after surgery in appropriate patients and in advanced disease. But the goal, duration and exact combination are not identical for everyone. Stage, tumor biology, response, side effects and the possibility of surgery or other local treatments can all influence how FOLFOX is used.
Sources
National Cancer Institute — Colon Cancer Treatment (PDQ)
Evidence-based information covering established treatment approaches for colon cancer, including systemic chemotherapy.
View NCI source →
International Journal of Surgery — Oxaliplatin-based adjuvant chemotherapy meta-analysis (2024)
Meta-analysis of randomized trials examining treatment duration and outcomes with oxaliplatin-based adjuvant chemotherapy in colorectal cancer.
View scientific evidence →
European Society for Medical Oncology — Metastatic colorectal cancer clinical practice guideline (2026)
Current ESMO clinical guidance for diagnosis, treatment and management of metastatic colorectal cancer.
View ESMO guideline →
Questions for your oncologist
If FOLFOX is part of your treatment plan, useful questions may include:
• What is the goal of FOLFOX in my situation?
• How many cycles are currently planned, and why?
• How will we know whether the treatment is working?
• Which side effects should I report immediately?
• What should I do if I develop tingling or numbness?
• Could my oxaliplatin dose or duration change if neuropathy develops?
• Have the important molecular biomarkers in my cancer been tested?
• If my cancer has spread, could treatment make surgery or another local treatment possible?
CancerSnoop note: This page provides evidence-based educational information and does not replace individual medical advice. Chemotherapy regimens, doses, treatment duration and treatment decisions should be discussed with your oncology team.
Related Posts
Comments (0)